The combination of Bristol Myers Squibb cancer drugs Opdivo and Yervoy landed FDA approvals for the first-line treatment of colorectal cancer and hepatocellular carcinoma. Several other products also expanded their approved uses in our recap of recent regulatory news.
The post BMS Immunotherapy Combo Gets Two FDA Nods for GI Cancers in Span of a Week appeared first on MedCity News.
